| abstract |
The invention provides an immune fusion protein capable of inhibiting T and B lymphocyte functions and a preparation method and an application thereof. The fusion protein is provided with functional zones of extracellular functional structural domains of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and a transmembrane activator and CAML interacter (TACI), can be specifically combined with an antigen presentation cell surface molecule B7 (CD80) and a B lymphocyte stimulator (BlyS) at high affinity, and has the capability of inhibiting activation of T and B lymphocytes. Autoimmunity diseases are diseases caused by hyper immunologic functions of T and B lymphocytes, so that an ultra-T/B immune fusion protein has the potential of treating diseases such as rheumatoid arthritis (RA), psoriasis, systemic lupus erythematosus (SLE), scleriasis, type I diabetes and the like. |